TrialGynecologic oncology2024

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.

Lilian T Gien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.